newsfilter
← Latest News
GlobeNewswire·

Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers

HSB-1216's active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomas HSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the FDA Rare Pediatric Disease (RPD) Designation and Orpha